Last reviewed · How we verify
OMP-52M51
At a glance
| Generic name | OMP-52M51 |
|---|---|
| Sponsor | OncoMed Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies (PHASE1)
- A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer (PHASE1)
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors (PHASE1)
- Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMP-52M51 CI brief — competitive landscape report
- OMP-52M51 updates RSS · CI watch RSS
- OncoMed Pharmaceuticals, Inc. portfolio CI